The

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Re	eduction Act of 1995, no person	ns are required to respond to a coll	ection of inforn	mation unless it	displays a valid OMB control number
	486	Application Number	10/706,	599	
TRANS	MITTALP	Filing Date	Novemb	per 11, 20	003
FO	R M ซึ	First Named Inventor	Jackow	ski	
•	JUN 0 9 2006	Art Unit	1641	1	
(to be used for all corresp	onde of after initial filing)	Examiner Name	. "		
Total Number of Pages in		Attorney Docket Number	2132.13	35	
Total Number of Pages in	This Submission Devices		12.102.10		
<u> </u>	ENC	LOSURES (Check all	that apply)		
Fee Transmittal Fo	eclaration(s) Request nent Request	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatior Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	ddress L	of App Appea (Appea Proprie	Enclosure(s) (please Identify
Certified Copy of P Document(s) Reply to Missing P Incomplete Applica Reply to Mi under 37 C	arts/ ition ssing Parts FR 1.52 or 1.53	OF APPLICANT, ATTOR	RNEY, OR	AGENT	
Firm Name	cHale & Slavin, P.	٨	· · · · · · · · · · · · · · · · · · ·		· .
Signature	Ji laig & Glavill, P.	<u></u>			
Pe	vid He Care			_	
Printed name Fe	erris H. Lander				
Date	15/2006	R	teg. No. 4	3,377	
	/ •/				
<i></i>	CERTIFIC	CATE OF TRANSMISSI	ON/MAILI	NG	
I hereby certify that this cor sufficient postage as first of the date shown below:	respondence is being facsi lass mail in an envelope ad	imile transmitted to the USPTC Idressed to: Commissioner for	or deposited Patents, P.O	d with the Uni). Box 1450, A	ted States Postal Service with slexandria, VA 22313-1450 on
Signature	D				
Typed or printed name	Debra N. Gerster	meier		Date	65200

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (10-04v2)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

(\$) 180.00TOTAL AMOUNT OF PAYMENT

C	omplete if Known	
Application Number	10/706,599	
Filing Date	11/11/2003	
First Named Inventor	George Jackowski	
Examiner Name	Changhwa J. Cheu	
Art Unit	1641	
Attorney Docket No.	2132.135	

METH	OD OF PA	YMENT (check all that	apply)				FE	E CALCULATION (continued)	
Check	Credit care	d Money Othe	er None	3. A	DDITI	ONA	L FEE	S	
Deposit	Account:	- Older -		<u>Large</u>	Entity	Small	Entity		
Deposit Account	50-1803			Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Number	00 1000			1051	130	2051	65	Surcharge - late filing fee or oath	
Deposit Account Name	Nanogen	1		1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
	s authorized t	to: (check all that apply)		1053	130	1053	130	Non-English specification	
✓ Charge fee		· <u> </u>	verpayments	1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
		e(s) or any underpayment of	f fee(s)	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	İ
Charge fee to the above-id	• •	elow, except for the filing	fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
to the above-io				1251	120	2251	60	Extension for reply within first month	
4 DAGIO E		CALCULATION		1252	450	2252	225	Extension for reply within second month	
1. BASIC F				1253	1,020	2253	510	Extension for reply within third month	
Fee Fee	Fee Fee	Fee Description	Fee Paid	1254	1,590	2254		Extension for reply within fourth month	
Code (\$) 1001 790	Code (\$) 2001 395	Utility filing fee		1255	2,160	2255		Extension for reply within fifth month	
1002 350	2002 175	Design filing fee		1401	500	2401	250	Notice of Appeal	
1003 550	2003 275	Plant filing fee		1402	500	2402		Filing a brief in support of an appeal	-
1004 790	2004 395	Reissue filing fee		1403	1,000	2403	500	Request for oral hearing	
1005 200	2005 100	Provisional filing fee		1451	1,510	1451	1,510	Petition to institute a public use proceeding	
	[SUBTOTAL (1) (\$)		1452	500	2452	250	Petition to revive - unavoidable	
. = :/==				1453	1,500	2453	750	Petition to revive - unintentional	
2. EXTRA C	JLAIM FEE	S FOR UTILITY ANI		1501	1,400	2501	700	Utility issue fee (or reissue)	
T		Extra Claims below		1502	800	2502	400	Design issue fee	
Total Claims Independent)** =	┦╄┻┻╣	1503	1,100	2503	550	Plant issue fee	
Claims Multiple Deper	-	s** = L X	┦╄┻┻┩	1460	130	1460	130	Petitions to the Commissioner	
		<u> </u>	┛╣	1807	50	1807	7 50	Processing fee under 37 CFR 1.17(q)	
Large Entity Fee Fee	Small Entity Fee Fee	Y Fee Description		1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
Code (\$)	Code (\$)			8021	40	802	1 40	Recording each patent assignment per property (times number of properties)	
1202 50 1201 200	2202 2 2201 10	-	excess of 3	1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1203 360	2203 18	•		1810	790	2810	395	For each additional invention to be	
1204 200	2204 10		t claims					examined (37 CFR 1.129(b))	
		over original patent		1801	790	2801		Request for Continued Examination (RCE)	
1205 50	2205 25	5 ** Reissue claims in ex and over original pate		1802	900	1802	900	Request for expedited examination of a design application	
	SU	BTOTAL (2) (\$)			fee (sp				
**or number		id, if greater; For Reissues,	see above	*Redu	iced by	Basic I	Filing F	ee Paid SUBTOTAL (3) (\$) 180.0	0

SUBMITTED BY (Complete (if applicable)) Registration No. Name (Print/Type) Ferris H. Lander 43,377 Telephone (561) 625-6575 Signature

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: George Jackowski et al

INVENTION

DIAGNOSTIC METHODS FOR CONGESTIVE

THEART FAILURE

SERIAL NUMBER

0/706,599

FILING DATE

: November 11, 2003

EXAMINER

GROUP ART UNIT

: 1641

ATTORNEY DOCKET NO.

: 2132.135

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the Duty to Disclose under 37 CFR §1.56, the references cited on the accompanying form PTO/SB/08A are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in the specification and their relevancy is set forth therein.

Because this Information Disclosure Statement is submitted after receipt of a substantive Office Action on the merits, the Commissioner for Patents is hereby authorized to charge the appropriate fee of \$180.00 required under 37 CFR \$1.17(p) to Deposit Account No. 50-1803.

Applicants submit that the present invention is patentable over these references.

Respectfully submitted,

Ferris H. Lander

Registration No. 43,377

McHale & Slavin, P.A.

2855 PGA Boulevard

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575 Facsimile: (561) 625-6572

06/09/2006 CNGUYEN2 00000067 501803 10706599

01 FC:1806

180.00 DA

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Parthwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

or form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Co	mplete if Known	
Application Number	10/706,599	
Filing Date	November 11, 2003	
First Named Inventor	Jackowski	
Art Unit	1641	
Examiner Name		
Attorney Docket Number	2132.135	

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		I I C		<u> </u>	
		^{US-} 6,572,895	06-03-2003	Smith et al.	
		US-			
		US-			
		US-	-		
		US-			
· _		US-			
	T	US-			
		US-			
	1	US-		<u> </u>	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	· ppca.n.c. oxod occa.no.n.	Or Relevant Figures Appear	
						L
						L
						Ĺ
						L
	l					Γ

Examiner	Da		
Signature	i Co	onsidered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/F				n of information unless it contains a valid OMB control number. Complete if Known
				Application Number	10/706,599
l			CLOSURE	Filing Date	November 11, 2003
STA	TEMEN.	T BY A	PPLICANT	First Named Inventor	Jackowski
	(Use as man	y sheets as n	acassan/l	Art Unit	1641
			cocssary,	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	2132.135

_	T :=-:	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		G. CAIMI et al., "Erythrocyte Aggregation and Erythrocyte membrane properties in Type 2 Diabetes mellitus and in Vascular Atherosclerotic Disease", Thromb Haemost 83: 516-517 2000	
		H. DEMIROGLU et al., "Enhanced Erythrocyte Aggregation in Type 2 Diabetes with Late Complications", Experimental Clinical Endocrinol Diabetes 107 (1): 35-39 1999.	
		E. EYLAR et al., "The Contribution of Sialic Acid to the Surface Charge of the Erythrocyte", The Journal of Biological Chemistry 237(6): 1992-2000 1962.	
		M. GACZYNSKA et al., "Abnormal Degradation of Red Cell Membrane Proteins in Diabetes", Cytobios 75: 7-11 1993.	-
		B.D. HAMES et al., "Antibodies as Tools" Instant Notes: Biochemistry, 2nd edition, Springer-Verlag New York 2000, pages 112-114.	
	-	B.D. HAMES et al., "Integral Membrane Proteins" Instant Notes: Biochemistry, 2nd edition, Springer-Verlag New York 2000, pages 125, 126, and 130.	
		M. MARTINEZ et al., "Alterations in Erythrocyte Aggregability in Diabetics: The Influence of Plasmatic Fibrinogen and Phospholipids of the Red Blood Cell Membrane", Clinical Hemorheology and Microcirculation 18: 253-258	
		A. PIWOWAR et al., "Concentration of Leukocyte Elastase in Plasma and Polymorphonuclear Neutrophil Extracts in type 2 Diabetes", Clinical Chemistry Lab Medecine 38(12) 1257-1261 2000.	
		M. RASAMOELISOLO et al., "Fine Characterization of a Series of New Monoclonal Antibodies Directed against Glycophorin A", Vox Sanguinis 72: 185-191 1997.	
		A. SANTOS-SILVA et al., "Erythrocyte Damage and Leukocyte Activation in Ischemic Stroke", Clinica Chimica Acta 320: 29-35 2002.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	PRMATION DISCLOSURE TEMENT BY APPLICANT (Use as many sheets as necessary) Complete if Known 10/706,599 Filing Date November 11, 2003 First Named Inventor Jackowski Art Unit Examiner Name				
Substitute	e for form 1449/P10			Application Number	10/706,599
INFO	RMATION	DIS	CLOSURE	Filing Date	November 11, 2003
STA	TEMENT E	BY AI	PPLICANT	First Named Inventor	Jackowski
				Art Unit	1641
	(Use as many she	ets as ne	cessary)	Examiner Name	
Sheet	3	of	3	Attorney Docket Number	2132.135

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
IIIIIIIII	110.	number(s), publisher, city and/or country where published.	
		T. A. SCOTT et al., "Erythrocyte membrane", Concise Encyclopedia: Biochemistry and Molecular Biology, Third edition, Revised and Expanded, Walter de Gruyter, Berlin-New York 1997, pages 201-202.	
		L. SOLANG et al., "Diabetes Mellitus and Congestive Heart Failure", European Heart Journal 20: 789-795, 1999.	
		B. VENERANDO et al., "Acidic and Neutral Sialidase in the Erythrocyte Membrane of Type 2 Diabetic Patients", Blood 99 (3): 1064-1070 2002.	
		M. WEGNER et al., "Role of Neutral Endopeptidase 24.11 in AV Fistular Rat Model of Heart Failure", Cardiovascular Research 31: 891-898, 1996.	
		O. ZIEGLER et al. "Increased Erythrocyte Aggregation in insulin-Dependent Diabetes Mellitus and Its Relationship to Plasma Factors: A Multivariate Analysis", Metabolism 43 (9): 1182-1186, 1994.	
-			
	-		

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.